Researcher

    Benoît Mâsse , Ph.D.

    benoit.masse.2@umontreal.ca
    Benoît Mâsse
    Research Axis
    Infectious Diseases and Acute Care Axis
    Research Theme
    Infection, immunity and inflammation
    Address
    CHUSJ - Centre de Recherche

    Phone
    514 345-4931 #6232

    Title

    • Full Professor of Biostatistics, School of Public Health, Université de Montréal (2010)
    • Head, Doctoral program in Public Health, School of Public Health, Université de Montréal (2023)
    • Head, Master program in Clinical Sciences - applied clinical research tract, Faculté de médecine, Université de Montréal (2011)
    • Co-Head, Master program in Statistics -biostatistics tract, Université de Montréal (2018)

    Education

    • Ph.D. in Biostatistics with supporting program in Epidemiology, Department of Biostatistics, School of Public Health, University of North Carolina at Chapel Hill, 1988-1993.
    • Master of Sciences, Statistics, Department of Mathematics and Statistics, University of Montreal, 1985-1988.
    • Bachelor of Science, Mathematics, Department of Mathematics and Statistics, University of Montreal, 1982-1985.

    Research Interests

    I have been involved in HIV/AIDS and microbicide research efforts since 1995. I have significantly contributed to the design of several HIV prevention research trials, including preparedness studies, safety studies (Phase I and II), and efficacy trials (Phase IIB and III). I am currently the lead biostatistician in the Microbicide Trials Network (MTN). Recognizing the development of microbicides as an important priority in HIV/AIDS research, the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), established the MTN in 2006 as its newest of six NIAID-funded HIV/AIDS clinical trials networks.

    MTN’s research portfolio is designed to face the global urgency of the HIV/AIDS epidemic head-on. It includes studies considered among the most critically important for advancing the field of HIV prevention. Many of these trials are focused on assessing antiretroviral (ARV)-based microbicides and include studies designed to evaluate microbicides along with other promising HIV prevention approaches, such as the daily use of ARVs as pre-exposure prophylaxis (PrEP). MTN is the first research group that is evaluating in parallel a vaginal microbicide gel and PrEP in the same trial. Notably, the MTN is leading the first microbicide studies involving pregnant women and also conducting studies to evaluate the rectal safety of vaginal microbicides, an important step toward eventually developing a microbicide specifically formulated for rectal use. MTN comprises 13 clinical trial units with 20 clinical research sites located in 7 countries. The overall goal is to conduct scientifically rigorous and ethically sound safety and effectiveness clinical trials, which will support licensure of these products.

    My research interests are: between-host mathematical models of infectious disease transmission, statistical methodology for clinical trials data, analysis of data from clinical trials, statistical methods for HIV/AIDS and infectious diseases, and design and analysis of HIV prevention trials.

    Research Topics

    • Randomized clinical trial
    • Evaluative studies and quantitative methods
    • Mathematical modeling, applied statistics, and biostatistics
    • Immunology and immune responses
    • Infections
    • Preventive medicine
    • Infection prevention and control in populations
    • AIDS / HIV
    • Vaccination and vaccine development

    Career Summary

    After 11 years in the USA at the Fred Hutchinson Cancer Research Center as a Faculty Associate Member in the Vaccine and Infectious Disease Division, Dr. Mâsse moved back to Canada in 2010 and took a faculty appointment at U of Montreal as well as joining the Research Center at CHU-Ste-Justine. Dr. Mâsse has experience in conducting multi-country large international trials in USA, Brazil, Canada, China, India, Russia, and in many countries of Africa. He is an author of over 175+ peer-reviewed articles. Noteworthy, in 2006, Dr. Mâsse received a grant of over $US 25 million from the NIH as the Principal Investigator responsible for the Statistical Data Management Center for providing support to all international clinical studies conducted within the NIH Microbicide Trials Network. As well, he was the lead senior statistician for the landmark HPTN 052 trial and contributed significantly to the unique design of this trial. The study was designed to evaluate whether immediate versus delayed use of ART by HIV-infected individuals would reduce transmission of HIV to their HIV-uninfected partners. The study shows that initiation of ART by HIV-infected individuals substantially protected their HIV-uninfected sexual partners from acquiring HIV infection. HPTN 052 is the first RCT to show that treating an HIV-infected individual with ART can reduce the risk of sexual transmission of HIV to an uninfected partner. Based on these results, the HPTN 052 study was named Scientific Breakthrough of the Year in 2011 by Science journal.

    In 2014, Dr. Mâsse was chairing the International Data and Safety Monitoring Board (DSMB) for the Ebola vaccine trial in Guinea (Ebola: Ça Suffit). This was the first trial that showed the efficacy of the rVSV-ZEBOV vaccine. Subsequently, he was chairing the International DSMB for the vaccine expanded access study for the ongoing Ebola epidemic in the Democratic Republic of Congo.

    In December 2019, the National Geographic selected the HPTN 052 and the Ebola: Ça Suffit trials as the top 20 discoveries of the last decade (all research field combined).

    Dr. Mâsse has a strong expertise in the design of clinical trials and statistical methodology as well as having a very strong expertise in implementing data management system for large international multi-country clinical trials/cohort studies and in establishing coordinating centers for these.

     

    Publications

    • Chaillet N, Mâsse B, Grobman WA, Shorten A, Gauthier R, Rozenberg P, Dugas M, Pasquier JC,             Audibert F, Abenhaim HA, Demers S, Piedboeuf B, Fraser WD, Gagnon R, Gagné GP, Francoeur         D, Girard I, Duperron L, Bédard MJ, Johri M, Dubé E, Blouin S, Ducruet T, Girard M, Bujold E;      PRISMA Trial research group. Perinatal morbidity among women with a previous caesarean        delivery (PRISMA trial): a cluster-randomised trial. Lancet. 2024 Jan 6;403(10421):44-54. doi: 10.1016/S0140-6736(23)01855-X. Epub 2023 Dec 11. PMID: 38096892.
    • Guerby P, Audibert F, Johnson JA, Okun N, Giguère Y, Forest JC, Chaillet N, Mâsse B, Wright D, Ghesquiere L, Bujold E. Prospective Validation of First- Trimester Screening for Preterm Preeclampsia in Nulliparous Women (PREDICTION Study). Hypertension. 2024 May 6. doi: 10.1161/HYPERTENSIONAHA.123.22584. Epub ahead of print. PMID: 38708601.
    • Berger É, Larose MP, Capuano F, Letarte MJ, Geoffroy MC, Lupien S, Brendgen M, Boivin M, Vitaro F, Tremblay R, Mâsse B, Côté S, Ouellet-Morin I. Hair steroid before and after COVID-19 in preschoolers: the moderation of family characteristics. Psychoneuroendocrinology. 2024 May 8;166:107072. doi: 10.1016/j.psyneuen.2024.107072. Epub ahead of print. PMID: 3873378
    • Sériès T, Guillot M, Angoa G, Pronovost E, Ndiaye ABKT, Mohamed I, Simonyan D, Lavoie PM, Synnes A, Marc I; MOBYDIck trial group. Does Growth Velocity Affect Associations between Birth Weight and Neurodevelopment for Infants Born Very Preterm? J Pediatr. 2023 Sep;260:113531. doi: 10.1016/j.jpeds.2023.113531. Epub 2023 Jun 1. PMID: 37268036
    • Delfrate J, Girard-Bock C, Curnier D, Perie D, Cloutier A, Gascon G, Landry JS, Mâsse B, Stickland MK, Nuyt AM, Luu TM. Cardiopulmonary response to exercise in adults born very preterm. Eur Respir J. 2023 Sep 21:2300503. doi: 10.1183/13993003.00503-2023. Epub ahead ofprint.PMID:37734855
    • Massamba VK, Talbot D, Milot A, Trudel X, Dionne CE, Vézina M, Mâsse B, Gilbert-Ouimet M, Dagenais GR, Pearce N, Brisson C. Association between psychosocial work-related factors at midlife and arterial stiffness at older age in a prospective cohort of 1736 white-collar workers. BMJ Open. 2023 Sep 27;13(9):e073649. doi: 10.1136/bmjopen-2023-073649. PMID: 37758677; PMCID:PMC10537828
    • Simard MN, Lepage C, Gaudet I, Paquette N, Doussau A, Poirier NC, Beauchamp MH, Côté SM, Pinchefsky E, Brossard-Racine M, Mâsse B, Gallagher A. A Parent- child yoga intervention for reducing attention deficits in children with congenital heart disease: the Yoga for Little Hearts Feasibility Study Protocol. BMJ Open. 2023 Oct 17;13(10):e079407. doi: 10.1136/bmjopen-2023-079407.PMID:37848299;PMCID:PMC10582886
    • Duchaine CS, Brisson C, Diorio C, Talbot D, Maunsell E, Carmichael PH, Giguère Y, Gilbert-Ouimet M, Trudel X, Ndjaboué R, Vézina M, Milot A, Mâsse B, Dionne CE, Laurin D. Work-Related Psychosocial Factors and Global Cognitive Function: Are Telomere Length and Low-Grade Inflammation Potential Mediators of This Association? Int J Environ Res Public Health. 2023 Mar 10;20(6):4929. doi: 10.3390/ijerph20064929. PMID: 36981836; PMCID: PMC10049148
    • Guillot M, Synnes A, Pronovost E, Qureshi M, Daboval T, Caouette G, Olivier F, Bartholomew J, Mohamed I, Massé E, Afifi J, Hendson L, Lemyre B, Luu TM, Strueby L, Cieslak Z, Yusuf K, Pelligra G, Ducruet T, Ndiaye ABKT, Angoa G, Sériès T, Piedboeuf B, Nuyt AM, Fraser W, Mâsse B, Lacaze-Masmonteil T, Lavoie PM, Marc I. Maternal High-Dose DHA Supplementation and Neurodevelopment at 18-22 Months of Preterm Children. Pediatrics. 2022 Jul 1;150(1):e2021055819. doi: 10.1542/peds.2021-055819. PMID: 35652296
    • Mâsse B, Robitaille N, Lacroix J. Duration of Anticoagulant Treatment for Acute Provoked Venous Thromboembolism in Pediatric Patients. JAMA. 2022 Jan 11;327(2):124-125. doi: 10.1001/jama.2021.21890. PMID: 35015051
 

Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine